Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (28)

2023

  1. Tocilizumab-related hypertriglyceridemia is independent of key molecules regulating lipid metabolism

    European Journal of Clinical Investigation, Vol. 53, Núm. 9

2022

  1. Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer’s Disease APP/PS1 Mouse Model

    Neurotherapeutics, Vol. 19, Núm. 5, pp. 1566-1587

2021

  1. Geroscience in times of global pandemic by COVID-19

    Revista Espanola de Geriatria y Gerontologia, Vol. 56, Núm. 6, pp. 323-325

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2019

  1. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus

    American Journal of Transplantation, Vol. 19, Núm. 12, pp. 3240-3249

2018

  1. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease

    Experimental Neurology, Vol. 299, pp. 137-147

  2. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis

    Arthritis Research and Therapy, Vol. 20, Núm. 1

2017

  1. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells

    American Journal of Transplantation, Vol. 17, Núm. 11, pp. 2829-2840

2014

  1. Striatal vessels receive phosphorylated tyrosine hydroxylase-rich innervation from midbrain dopaminergic neurons

    Frontiers in Neuroanatomy, Vol. 8, Núm. AUG

2012

  1. Neonatal apneic seizure of occipital lobe origin: Continuous video-EEG recording

    Pediatrics, Vol. 129, Núm. 6

2007

  1. Cloning and functional expression of a new epithelial sodium channel δ subunit isoform differentially expressed in neurons of the human and monkey telencephalon

    Journal of Neurochemistry, Vol. 102, Núm. 4, pp. 1304-1315

2006

  1. Glycine release in the substantia nigra: Interaction with glutamate and GABA

    Neuropharmacology, Vol. 50, Núm. 5, pp. 548-557

2005

  1. Glial regulation of nonsynaptic extracellular glutamate in the substania nigra

    GLIA, Vol. 49, Núm. 1, pp. 134-142

  2. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells

    European Journal of Neuroscience, Vol. 21, Núm. 7, pp. 1815-1827

2004

  1. Effect of intracerebroventricular injection of lipopolysaccharide on the tuberoinfundibular dopaminergic system of the rat

    Neuroscience, Vol. 127, Núm. 1, pp. 251-259

  2. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons

    Journal of Comparative Neurology, Vol. 479, Núm. 2, pp. 198-215

  3. Extracellular Taurine in the Substantia Nigra: Taurine-Glutamate Interaction

    Journal of Neuroscience Research, Vol. 76, Núm. 4, pp. 528-538

  4. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat

    Movement Disorders, Vol. 19, Núm. 9, pp. 1029-1042

2003

  1. Effects of dopaminergic cell degeneration on electrophysiological characteristics and GAD65/GAD67 expression in the substantia nigra: Different action on GABA cell subpopulations

    Movement Disorders, Vol. 18, Núm. 3, pp. 254-266

2002

  1. Response of GABAergic cells in the deep mesencephalic nucleus to dopaminergic cell degeneration: An electrophysiological and in situ hybridization study

    Neuroscience, Vol. 113, Núm. 2, pp. 311-321